Manning & Napier Advisors LLC Has $27.32 Million Stake in Johnson & Johnson $JNJ

Manning & Napier Advisors LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 43.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,340 shares of the company’s stock after selling 115,040 shares during the period. Manning & Napier Advisors LLC’s holdings in Johnson & Johnson were worth $27,320,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. United Bank increased its holdings in Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC raised its stake in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after purchasing an additional 692 shares during the period. Sovran Advisors LLC lifted its holdings in shares of Johnson & Johnson by 7.2% in the second quarter. Sovran Advisors LLC now owns 6,323 shares of the company’s stock valued at $985,000 after purchasing an additional 422 shares in the last quarter. Finally, Secure Asset Management LLC boosted its position in shares of Johnson & Johnson by 8.2% during the second quarter. Secure Asset Management LLC now owns 4,981 shares of the company’s stock worth $761,000 after buying an additional 377 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $218.81 on Friday. The company has a market cap of $527.18 billion, a PE ratio of 21.12, a price-to-earnings-growth ratio of 2.26 and a beta of 0.34. The firm has a 50-day moving average of $205.82 and a 200-day moving average of $186.74. Johnson & Johnson has a one year low of $141.50 and a one year high of $220.11. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.76 by $0.04. The business had revenue of $23.99 billion during the quarter, compared to the consensus estimate of $23.73 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson’s revenue was up 6.8% on a year-over-year basis. During the same period last year, the business posted $2.42 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 50.19%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on JNJ shares. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research report on Monday, October 20th. Finally, Raymond James Financial lifted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.